Myovant's Next Act: Commercial Execution And Business Development

 
• By Jessica Merrill

The company is ramping up the launches of Orgovyx for prostate cancer and Myfembree for uterine fibroids, including indication and geographic expansions, and evaluating business development opportunities.

flower blossom
Myovant hopes its budding commercial brands will blossom • Source: Alamy

More from Strategy

More from Business